A strong and productive relationship between a sponsor and their clinical research organization (CRO) is crucial for the success of any clinical trial. When both parties have mutual trust, respect, and clear communication, it becomes significantly easier to stay on course and achieve the desired outcomes.
While proper vendor oversight can significantly reduce risks, unforeseen challenges may arise, leading to the need for contract termination and what is known in the industry as a "rescue study." However, it is essential not to make the decision to part ways with your CRO lightly.
Before considering terminating a contract, it is vital to contemplate several potential consequences. Nevertheless, if all other options have been exhausted, and a breakup is inevitable, having a well-thought-out exit strategy in place can alleviate some of the difficulties.
This white paper delves into the reasons to contemplate terminating a CRO contract, the potential implications of such a decision, and provides strategies for a successful exit and transition process.